Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture: A Single-Arm Prospective Study Compared to Historical Controls (STRIDE-HIP Study)

NCT07905404 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07905404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip Fracture: A Single-Arm Prospective Study Compared to Historical Controls (STRIDE-HIP Study)
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 5, 2027
Completion date
July 30, 2028
Enrollment
79 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hip fractures (icd-10 72.01-72.2), post operative analgesia

Arms

As registered; 2 arms.

  • Matched Historical Controls No intervention

    Historical controls will be selected at approximately a 2:1 ratio using prespecified clinical matching and propensity-score methods to improve comparability between cohorts. Historical controls will be matched on factors including age, sex, fracture type, surgery type, surgeon, ASA class, opioid-naïve status, regional anesthesia, and relevant comorbidities.

  • Suzetrigine + Standard Multimodal Analgesia ExperimentalSuzetrigine (Journavx)

    Participants undergoing operative treatment for acute hip fracture will receive suzetrigine in addition to standard-of-care multimodal analgesia

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Postoperative Opioid Consumption Rate From end of surgery through 72 hours postoperatively or hospital discharge, whichever occurs first

    Total opioid analgesic administration will be converted to morphine milligram equivalents (MME). Opioid consumption will be expressed as MME per hour during the primary postoperative observation window to account for differences in duration of hospitalization. Lower MME/hour indicates lower opioid consumption.

  • Cumulative Postoperative Opioid Consumption From end of surgery through 72 hours postoperatively or hospital discharge, whichever occurs first

    Total opioid analgesic administration during the primary postoperative observation window will be converted to cumulative morphine milligram equivalents (MME). Lower cumulative MME indicates lower total opioid exposure.

Lead sponsor's other trials

Beth Israel Deaconess Medical Center, most recent start first.

Similar trials

Same condition (Hip Fractures) and phase, most recent start first.